Amarantus Bioscience Holdings, Inc. announced that it has appointed Michael T. Ropacki, PhD as Chief Medical Advisor to the Company's Alzheimer's Blood Diagnostic LymPro Test program. Dr. Ropacki will be responsible for helping oversee the further development of LymPro and assist the management team currently being recruited to lead the Company's Neurodiagnostics division in raising capital for the soon-to-be-formed Neurodiagnostics subsidiary. Dr. Ropacki brings over 20 years of clinical development experience to Amarantus as an industry clinical leader, investigator (academic and industry) and consultant. Dr. Ropacki is the President of Strategic Global Research & Development (SG R&D). Prior to his role at SG R&D, Dr. Ropacki was most recently Senior Vice President of Clinical Development at MedAvante-ProPhase after its acquisition by WIRB Copernicus Group (WCG) in 2017. Before the WCG acquisition, he served as MedAvante's Vice President of Research & Development. Prior to his work at MedAvante, Dr. Ropacki held roles of increasing responsibility at Johnson & Johnson, his last as Director of Clinical Development, Neuroscience, Research and Development, for Janssen Research & Development.